Early Detection of Molecular Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor DNA.

Thus, ctDNA-based MRD monitoring appears to be a promising option to complement the overall assessment of pediatric AML patients, wherein patients with continuous ctDNA negativity have the option for treatment de-escalation in subsequent therapy. Importantly, patients with >3 log reduction but without clearance in ctDNA may not necessitate an aggressive treatment plan due to improved survival, but this needs further study to delineate.